Drug Profile
Carbon monoxide inhalation - Mallinckrodt
Alternative Names: CovoxLatest Information Update: 14 Oct 2021
Price :
$50
*
At a glance
- Originator Ikaria Holdings
- Developer Mallinckrodt plc
- Class Anti-inflammatories; Inorganic carbon compounds; Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Renal transplant rejection
Most Recent Events
- 16 Apr 2015 Ikaria Holdings has been acquired by Mallinckrodt plc
- 28 Jul 2008 Carbon monoxide inhalation receives Orphan Drug status for Renal transplant rejection in USA
- 15 Feb 2008 Phase-II clinical trials in Renal transplant rejection in USA (Inhalation)